Inhibrx Boosts Liquidity with $500M Oxford Loan Facility, but Core BLA and Safety Risks Persist

What happened

Inhibrx amended its loan agreement with Oxford Finance, expanding the total facility to $500 million and providing an immediate $100 million tranche with potential for an additional $225 million at Oxford's discretion. The additional capital extends the company's cash runway as it prepares for a planned Q2 2026 ozekibart BLA submission, but the newly added debt increases fixed interest expense and exposes the company to lender discretion for future tranches. The loan amendment does not alter the fundamental risk profile: the stock's valuation remains tightly coupled to successful BLA filing and manageable FDA review of hepatotoxicity signals. While the financing reduces near-term dilution risk, it adds financial leverage and does not address the binding constraints of CMC readiness or liver safety. Inhibrx's path to value creation still hinges on flawless execution of its regulatory strategy, with the loan serving as a bridge that also introduces additional creditor oversight.

Implication

Investors should view this as a prudent liquidity move that reduces near-term financing risk, but it does not change the core thesis that INBX remains a high-risk, binary play on ozekibart BLA submission and FDA safety review. The discretionary tranche gives Oxford leverage, and the increased debt load could pressure equity if timelines slip. We maintain a WAIT rating, looking for a more attractive entry near $60 or a filing-readiness confirmation before committing capital.

Thesis delta

This news does not shift the investment thesis; it extends the cash runway but adds financial obligations. The loan reduces short-term bankruptcy risk but does not de-risk the regulatory path. Core catalysts and risks remain unchanged.